Upfront Briefing
Lilly's blowout Q1 (revenue +56% to $19.8B, FY26 guide raised by $2B, Foundayo launching) reset the pharma/biotech narrative — the GLP-1 macro just got louder, and biotech joined the risk-on tape.
The IPO window stayed wide: Hemab and Seaport priced for ~$556M combined, taking 2026 to 10 IPOs — already eclipsing all of 2025 and the strongest start since 2021.
Elsewhere: Merck beat and raised guidance (offset by a $9B Cidara charge), LEO Pharma bought Replay for $50M upfront to enter dermatology gene therapy, uniQure pivoted AMT-130 toward a Q3 UK filing after the FDA quarrel, and Telix's Pixlumi MAA was validated in Europe.
Tape Action
| Instrument |
Last close |
1D % |
YTD % |
| S&P 500 |
7,209.0 |
+1.0% |
+5.3% |
| Nasdaq 100 |
27,452.1 |
+1.0% |
+8.9% |
| Russell 2000 |
2,799.9 |
+2.2% |
+12.8% |
| Healthcare (XLV) |
146.0 |
+2.2% |
(5.1%) |
| Biotech (XBI) |
131.3 |
+1.9% |
+9.6% |
| Nasdaq Biotech (NBI) |
5,862.9 |
+1.9% |
+2.3% |
| Clinical Trials (BBC) |
43.9 |
+2.6% |
+17.4% |
|
- A clean risk-on flip after Wednesday's Fed/oil-driven selloff: Russell 2000 +2.2%, S&P 500 +1.0%, on better-than-feared Mag 7 earnings (Meta, Microsoft, Alphabet results all helped tone), softer Brent on incremental Iran de-escalation chatter, and a string of pharma beats that included Lilly, Merck and AstraZeneca.
- Biotech beta finally joined rather than lagged the move — XBI +1.9%, NBI +1.9%, BBC +2.6% — helped by single-name strength in Lilly after its Q1 beat-and-raise, continued IPO momentum (Avalyn debut Wed, Hemab/Seaport pricing Thu) and resilient sector breadth.
- Market data: U.S. close Thu 30-Apr-2026.
The Big 3
|
1
|
Hemab and Seaport extend the biotech IPO run
|
- Hemab Therapeutics priced an upsized IPO of 16.75M shares at $18 for ~$301.5M (Goldman/Jefferies/Evercore book), and Seaport Therapeutics priced ~14M shares at $18 for ~$254.9M — combined ~$556M. Both begin trading Friday under COAG and SPTX. With Avalyn pricing Wednesday, this is three IPOs in one week and takes 2026 to 10 IPOs for ~$3.2B — already eclipsing all of 2025.
- Why it matters: (1) Hemab: Lead asset sutacimig (HMB-001) is a bispecific antibody headed to Phase 3 in Glanzmann thrombasthenia in 2H26, with Phase 2 Factor VII deficiency data due late-2026/early-2027 and HMB-002 in Phase 1/2 for von Willebrand Disease — gives investors a rare-bleeding franchise comp at a $1B+ post-money market cap, with RA Capital and Novo Holdings as anchor holders. (2) Seaport: First neuropsychiatry IPO of 2026; the read-through here is for the Karuna/Cobenfy-era CNS comp set — investors are willing to underwrite a multi-asset Phase 2 CNS platform at scale again. (3) Window: Six of 2026's ten IPOs have cleared $300M, a benchmark rarely seen since 2021 — the test now shifts from "can they price?" to "can they trade?" Aftermarket performance over the next 5–10 sessions will set the benchmark for the next wave of S-1s sitting in the queue.
- Source: BioPharma Dive; Hemab PR
|
|
2
|
Lilly's Q1 blowout resets the GLP-1 macro
|
- Lilly delivered Q1 revenue of $19.8B (+56% YoY) and adjusted EPS of $8.55 vs. $6.97 consensus — a 22.7% beat. Mounjaro $8.66B (+125%) and Zepbound ~$4.2B (+80%) were the engines; FY26 revenue guide was raised $2B to $82–85B and EPS to $35.50–$37 from $33.50–$35. Shares were +7% in pre-market trading.
- Why it matters: (1) Asset: Foundayo (orforglipron), Lilly's oral GLP-1 for adults with obesity or overweight with weight-related medical problems, is now approved and in launch mode, with Lilly citing early patient uptake and planned broader promotion. The launch trajectory matters because it will test how much incremental demand exists beyond injectables and how quickly payers / prescribers absorb another high-volume obesity product. (2) Macro: A +56% top-line print at $19.8B run-rate is the cleanest validation yet that GLP-1 demand is supply-constrained, not demand-constrained — the 65% volume growth absorbed a 13% price decline without breaking the model. (3) Read-through: Bullish for the entire metabolic/obesity cohort (Viking, Structure, Altimmune, Boehringer's preclinical pipeline) and supportive for any company with downstream GLP-1 manufacturing exposure (CDMOs, fill-finish capacity); slightly bearish for Novo's competitive narrative ahead of its print next week.
- Source: CNBC; PR
|
|
3
|
LEO Pharma buys Replay to enter dermatology gene therapy
|
- Denmark's LEO Pharma agreed to acquire San Diego-based Replay for $50M upfront plus milestones and tiered single-digit royalties, picking up an HSV-based gene therapy platform delivered as a topical gel. Lead program targets dystrophic epidermolysis bullosa (DEB), a devastating rare genetic skin disease with significant unmet need.
- Why it matters: (1) Asset: HSV's high payload capacity is mechanistically suited to large-gene rare skin diseases like DEB, where AAV's payload limit has frustrated prior attempts; topical gel delivery side-steps the systemic immunogenicity issues that have dogged systemic AAV programs. (2) Pricing: $50M upfront for a preclinical platform with a focused dermatology buyer is cheap optionality — sets a low comp for HSV-vector platforms more broadly (read-through for Krystal Biotech's adjacent Vyjuvek franchise and other topical gene-therapy plays). (3) Strategic: LEO is a private dermatology specialist; this is its first gene-therapy move and slots alongside its 2023 Timber Pharmaceuticals deal as evidence of a focused rare-skin acquisition strategy. The implicit message to dermatology biotechs: even non-Big-Pharma strategics are now buying preclinical platforms at clean upfronts.
- Source: Reuters; PR
|
Everything Else that broke
- Merck Q1 revenue $16.29B (+5%, beat), narrows and raises 2026 guide to $65.8–67.0B / $5.04–5.16 EPS; reports GAAP loss after $9B Cidara acquisition charge; Keytruda +12% to $8.03B incl. $128M from subcutaneous Qlex. — CNBC
- uniQure says UK MHRA pre-submission meeting was successful; plans Q3 2026 MAA filing for AMT-130 in Huntington's, based on the same Phase 1/2 75% slowing data the FDA recently said needs a sham-controlled study — clear regulatory divergence between UK and US. — BioSpace
- Telix's TLX101-Px (Pixlumi) MAA validated and accepted by EMA, entering 210-day active assessment; alongside the recent U.S. NDA acceptance, gives Telix a clearer dual-region launch path for its ^18F-FET PET glioma imaging asset. — PR
- Restore Vision shares first-in-human interim RV-001 data — a GPCR-based optogenetic gene therapy for vision restoration. — PR
- FDA names Katherine Szarama acting director of CBER. — STAT
- Larimar publishes cross-species data backing skin as a surrogate biomarker for frataxin in tissues clinically relevant to Friedreich's Ataxia. — PR
- Pacira BioSciences and Syndax both report Q1 2026 financial results. — Pacira; Syndax
- DBV Technologies reports Q1 2026 financial results. — PR
- Kodiak to present KSI-101 clinical data, including Phase 1b MESI cohort results, at upcoming conferences. — PR
- Totus to present interim Phase 1b TOS-358 + fulvestrant doublet data in HR+/HER2– breast cancer at ESMO Breast 2026. — PR
Deal Flow
| BioBucks 2026 Deal Trackers • Updated weekly ⬇️
|
M&A / BD&L
-
LEO Pharma to acquire Replay for $50M upfront plus milestones and tiered royalties, adding a dermatology-focused gene therapy platform and a preclinical dystrophic epidermolysis bullosa program. — Reuters
VC / Private Financings
- No new notable VC / Private financings since yesterday's edition
IPOs / Follow-Ons / PIPEs
- Hemab Therapeutics prices upsized IPO, raising ~$301.5M at $18/share; expected to trade under COAG. — PR
- Seaport Therapeutics prices IPO, raising ~$254.9M at $18/share; expected to trade under SPTX. — BioPharma Dive
- Rein Therapeutics prices $50M underwritten offering of common stock, with no warrants. — PR
- Cue Biopharma announces $30M private placement, expected to close around 4 May. — PR
Academic Corner - Once-weekly semaglutide versus placebo in patients with alcohol use disorder and comorbid obesity: a randomised, double-blind, placebo-controlled trial. — Lancet
- Uncovering risk factors in the exposome for early-onset colorectal cancer. — Nature Medicine
|
